Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas

This study tests whether a drug called pemigatinib — which targets a protein called FGFR that can drive cancer cell growth — can help people with certain types of B-cell lymphoma (a blood cancer) that has returned or stopped responding to previous treatments. The specific lymphoma types studied include mantle cell lymphoma (MCL) and marginal zone lymphoma (MZL). **You may be eligible if...** - You are 18 years or older - You have confirmed MCL or MZL that has relapsed or is not responding to treatment - You have received at least two prior treatment regimens and have no other standard options available (or have refused them) - You are in reasonably good health (ECOG score 0–2) - Prior stem cell transplant or CAR-T cell therapy is allowed **You may NOT be eligible if...** - You have not tried at least two prior treatments - You have certain serious health conditions affecting your heart, liver, or eyes - You are pregnant or breastfeeding - You are currently receiving treatments that interact with this drug Talk to your doctor to see if this trial is right for you.